In Brief: DePuy
This article was originally published in The Gray Sheet
Executive Summary
DePuy: Gains FDA approval for its Endurance polymethylmethacrylate bone cement, which is intended for use "to fix joint reconstructive implants, primarily hips and knees, in the replacement of worn or damaged joints," the Warsaw, Indiana firm explains. Separately, DePuy says it plans to commence Phase I clinical trials by year-end of its SIS product, derived from the small-intestinal submucosa of pigs, for replacement of ruptured anterior cruciate ligaments of the knee. The initial studies will include 12 patients to be treated at two U.S. sites...